Abstract:Gastric cancer (GC) is one of the most commonly occuring gastrointestinal tumor types, and early diagnosis and operation have a notable effect on the prognosis of patients. Although certain markers, including HER2, VEGER-2, ERCC1 and Bcl-2, have been utilized in clinical practise to screen out new patients with GC, the results of using these markers remains poor. The role of olfactomedin-like 2B (OLFML2B) in GC, as a member of the olfactomedin domain-containing proteins family, is remain unclear. In the present study, we assessed the expression of OLFML2B, including mRNA and protein level, by using The Cancer Genome Atlas (TCGA) database and 13 pairs of clinical samples between GC and NG tissues. The correlation between expression of OLFML2B and prognosis of GC was evaculated by the Kaplan-Meier plotter and OncoLnc online tools. In addition, mechanism analysis of OLFML2B in GC was explored thought bioinformatic tools, including cBioPortal and FunRich software. In our study, the mRNA expression of OLFML2B in GC both TCGA database and clinical samples was consistently revealed to be significantly higher compared with that in NG tissues (P < 0.0001 for TCGA database and P = 0.0034 for clinical samples), and high OLFML2B expression was found in 9 (69.23%) of 13 clinical GC by immunohistochemistry and was positively correlated with the depth of tumor invasion and clinical stage (TNM). In addition, the AUC for a ROC of 0.867 indicated a moderate diagnostic ability of OLFML2B for GC. Survival analysis from the Kaplan-Meier plotter (P = 2.6 × 10− 6) and OncoLnc (P = 0.00276) revealed that the high expression of OLFML2B was associated with a short overall survival. Futhermore, 5% (24/478) alterations of OLFML2B were identified from cBioPortal, and among them, missense mutation (14/478) was the primary type. The results from FunRich revealed that OLFML2B participated in mediating multiple biological processes including cell growth and maintenance, regulation of the cell cycle, apoptosis and cell communication through multiple signaling pathways including the M/G1 transition pathway, post-translational protein modification and DNA replication pre-initiation. Taken together, it could be deduced that OLFML2B may act as an oncogene in the development of GC and the overexpression of OLFML2B in GC may be used as a novel diagnostic and prognostic target for GC.

OLFML2A Downregulation Inhibits Glioma Proliferation Through Suppression of Wnt/β-Catenin Signaling

OLFML2A Downregulation Inhibits Glioma Proliferation Through Suppression of Wnt/β-Catenin Signaling

miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase.

GeneChip expression profiling identified OLFML2A as a potential therapeutic target in TNBC cells

Knockdown of Lncrna HOXD-AS2 Improves the Prognosis of Glioma Patients by Inhibiting the Proliferation and Migration of Glioma Cells

AMOTL2‑knockdown Promotes the Proliferation, Migration and Invasion of Glioma by Regulating Β‑catenin Nuclear Localization.

A Novel Lncrna‐linc01116 Regulates Tumorigenesis of Glioma by Targeting VEGFA

Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas

LOXL1 confers antiapoptosis and promotes gliomagenesis through stabilizing BAG2

Pan-Cancer Analysis of OLFML2B Expression and Its Association With Prognosis and Immune Infiltration

LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT

Bioinformatic Exploration of OLFML2B Overexpression in Gastric Cancer Base on Multiple Analyzing Tools

GOLM1 Silencing Inhibits the Proliferation and Motility of Human Glioblastoma Cells Via the Wnt/β-catenin Signaling Pathway.

Long Noncoding RNA AB073614 Promotes the Malignance of Glioma by Activating Wnt/β-catenin Signaling Through Downregulating SOX7.

OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts

Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma

ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma

Silencing of Lncrna LBX2-AS1 Suppresses Glioma Cell Proliferation and Metastasis Through the Akt/GSK3β Pathway in Vitro.

Discovery of LAMP-2A as potential biomarkers for glioblastoma development by modulating apoptosis through N-CoR degradation

OLFML2A is Necessary for Anti-Triple Negative Breast Cancer Effect of Selective Activator Protein‐1 Inhibitor T-5224

A novel function of OLIG2 to suppress human glial tumor cell growth via p27Kip1 transactivation